Targovax has received very positive results regarding the survival rate of patients with pancreatic cancer. Immune-oncology aims to help the body’s own immune system fight cancer and the ambition is to address the unmet need for long-term survival for patients with advanced cancers. 13 of 13 The company specializes in immune-oncology and is a member […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 293 entries.
Entries by oslocancer
En kortere versjon av denne kronikken sto på trykk i Aftenposten 13.10.2017. Du kan lese innlegget i Aftenposten her. Vi må forhindre at digital helse blir digitalt kvakksalveri. Hva får vi hvis vi smelter sammen teknologi og biologi? Jo, digital helse. Her finner vi et kinderegg for pasienter, leger og forskere. Det inneholder unike muligheter til […]
Curida has come a long way from defending their place at the Norwegian factory to setting their sights internationally. What is Curida and their goal all about? Creating value within ones own country while steadily spreading roots globally is no easy feat, but the young Norwegian pharmaceutical company Curida is blooming. Overcoming the threat at Elverum […]
Luckily, all our events at Oslo Innovation Week and Forskningsdagene are available for a rerun. Have a look! We had great audiences during our three events on the 27th and 28th of September. If your were not among them, sitting in the brand new science centre of the Norwegian Cancer Society, do not despair. The events were all live […]
The innovation company of the year wants to encourage young talents. Six students from Ullern Upper Secondary School spent their school day at Thermo Fisher Scientific just days after the company won the prestigious award as the innovation company of the year in Norway. As part of the school collaboration between Ullern Upper Secondary School and […]
A new Norwegian research collaboration helps uncover what treatments are the right fit for American cancer patients. Who are the collaborators and what are they doing? There’s a lot of excitement and optimism concerning immuno-oncology, where the method is to utilize a person’s own immune system to treat cancer. However, excitement aside, methods such as this are often a costly experience, […]
Stanford programme SPARK provides a shimmer of hope for startup companies. Now, SPARK sets sights on Norway. What exactly is SPARK? We live in a world where technological and innovative solutions in medicine and healthcare are steadily pouring in. Not to mention, these solutions have the power to completely transform the health-sector in pinpointing and […]
Photocure reveals promising results in bladder cancer through the use of Blue Light Cytoscopy alongside the drug Hexvix. Bladder cancer endangers 167,000 people in Europe annually followed by over 59,000 deaths. Men are especially at risk, where a staggering 75% of bladder cancer cases occur. Not only that, but bladder cancer has a reputation as being one […]
On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway. The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, […]
We are proud to introduce Oslo Cancer Cluster’s new members. This is the second part of two stories about our new members. You can find the first part HERE. On the 24th of August, Oslo Cancer Cluster hosted a bustling summer party in the Oslo Cancer Cluster Incubator, where the new members had the chance to introduce […]
Contact Team >
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.